Miry Blich received her MD (1999) from the Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. She completed three residencies at Rambam Health Care campus: internal medicine (2000–2004), cardiology (2004–2007), and electrophysiology (2007–2010). Dr Blich also completed a fellowship in inherited arrhythmia syndromes from Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy (2010-2011) and a fellowship in inherited cardiomyopathies in inherited cardiovascular disease unit, the heart hospital UCL, London, UK (2014). In 2011, Dr. Blich founded the Inherited Arrhythmia Clinic at Rambam— The clinic specialized in the diagnosis, treatment and long term follow up of patients with inherited cardiomyopathies and inherited channelopathies- two leading causes of heart failure and sudden cardiac arrest in the young. The clinic was the first in Israel to perform routine genetic testing for every patient who was suspected to have inherited heart disease and to use the genetic testing as a clinical routine tool for diagnosis, risk assessment and treatment selection in these challenging patients. The uniqueness of the clinic is this pioneering approach that combines comprehensive   cardiac evaluation and the genetic diagnosis. Today the clinic serves over 1800 patients from across Israel and is a national leader in its field. Since 2011 Miry Blich is a Senior Cardiologist in the Department of Cardiology and in the Electrophysiology Unit at Rambam, and is Head of the Inherited Arrhythmia Clinic and Women’s Heart Clinic. In addition to her clinical work, Dr. Blich is involved in clinical and basis research. She has received several prizes, including the Neufeld Award for original research work from the Israel Heart Society in 2012, and has authored several scientific publications.

Rodney Falk is the Founder and Emeritus Director of the Brigham and Women’s Hospital Amyloidosis Program, and Associate Professor of Medicine at Harvard Medical School. Boston MA USA. He has been involved with treating patients with amyloidosis for over 40 years and was previously at Boston University where he was a Professor of Medicine and Associate Director of The Boston University Amyloidosis Program. Dr Falk is a senior author or co-author on over 250 peer publications and has lectured nationally and internationally on cardiac topics in general and amyloid heart disease in particular.

Prof. Michal Laufer Perl is a senior cardiologist specializing in heart failure and cardio-oncology. She is the Director of the Cardiovascular Clinics and Heart Failure Service and serves as Secretary of the Cardiomyopathy Section for the Israel Cardiology Association.

Jonathon A. Leipsic, M.D., F.R.C.P.C. M.S.C.C.T is Professor and Chair of Radiology and Professor of Cardiology with the University of British Columbia and previously held a Canada Research Chair of Cardiac Imaging. Dr. Leipsic has over 870 peer reviewed manuscripts in press or in print, over 300 scientific abstracts, and editor of 2 textbooks. He speaks internationally on a number of cardiopulmonary imaging topics with over 150 invited lectures in the last 4 years. He is also past President of the Society of Cardiovascular CT (2015-2016) and was awarded its Gold Medal in 2019 and was recently named to the prestigious Top 1% most impactful scientist designation by the Web of Science for 6 years in a row from 2019-2024.

Dr Matetzky graduated cum laude from the Sackler School of Medicine, Tel Aviv University. He continued his studies specializing in Internal Medicine and Cardiology at the Sheba Medical Center.

From 1998 to 2001 Dr Matetzky specialized in Intensive Care Cardiology at Cedars Sinai in Los Angeles USA. During his fellowship Prof Matetzky researched myocardial infarcts and atherosclerosis in the young and the correlation between coagulation disturbance and myocardial infarction. His fellowship included laboratory work as a research team member of one of the renowned laboratories in this field at UCLA – Atherosclerosis Research Center, especially in Atherosclerotic Plaque thrombogenecity.

Dr Matetzky has an academic track professorship in Cardiology and Internal Medicine from the Tel Aviv University.

Currently Dr Matetzky is the Director of Cardiovascular Hospitalization and the Cardiac Intensive Care Unit, as well as in recent years being appointed Deputy Director of the Division of Cardiology in the Sheba Medical Center, Israel.

Dr Matetzky established a Clinic for premature infarcts/atherosclerosis in the Sheba Medical Center dealing with treatment for young cardiac patients with emphasize on diagnosis and treatment of hypercoagulable states.

In 2016 he set up a Chest Pain Center (CPC) in the Sheba Medical Center to identify and treat patients suffering from chest pain and suspected coronary disease. After evaluating over 15,000 patients with suspected coronary events the unit was enlarged to include a Fast Track Evaluation for patients with low risk pulmonary emboli and DVT as an innovative approach to providing a remarkable service to treat these patients at Sheba.

Dr Matetzky is a member of the Medical Board of Magen David Adom (Israeli national EMS) and is senior consulting cardiologist to the Israeli Airforce holding the position of Lieutenant Colonel.

Over the last decade Prof Matetzky has fulfilled number of positions in the Israel Heart Society. Among them he was head of the working group for intensive cardiac care (ACCA) and currently is head of the Working Group for Cardiovascular Pharmacotherapy. Within the framework of his duties Prof Matetzky was responsible for the Acute Coronary Syndrome Israeli Survey (ACSIS).

Prof Matetzky was a co-author of the Guidelines for the Israel Heart Society.

Prof Matetzky is a member of many professional societies: IHS, ESC and ISTH as well as professional forums such as the Pulmonary Embolism Expert Forum (PEEF) and ICHOM (International Consortium for Health Outcomes Measurement). In this framework he initiated the PROM program for cardiology patients at Sheba.

Prof Matetzky is a member of the organizing committee of several local and internationl conferences including ICI and ACCA.

He was awarded the prestigious Mirowsky Prize for excellence in cardiology.

Prof Matetzky is an active lecturer and teacher in the Sackler Faculty of Medicine at Tel Aviv University.

Prof Matetzky has published over 150 manuscripts in prestigious scientific journals, including many manuscripts in the field of platelet function in coronary patients and their response to anti-platelet agents as well as laboratory studies on basic science in the field of atherothrombosis.

Main topics of Prof Matetzky’s research include clinical studies in AMI patients, treatment of acute coronary episodes, and specifically platelet function in patients with ACS, platelet responsiveness to anti- platelet agents in ACS and post PCI as well as ex-vivo and laboratory studies platelets function. Further research topics include the pathogenesis of premature coronary events and coagulation disorders. Recently Prof Matetzky has been involved in research in the field of vascular medicine, especially regarding the significance of PAD in coronary patients and predictors and pathogenesis of pulmonary emboli. Most recently Prof Matetzky initiated and now heads a large prospective registry of hospitalized PE patients and is involved in a number of studies on the prognostication and treatment PE patients.

• Chief, Department of Cardiology, Hôpital Bichat, Paris, France.
• Vice President (Research) of the board of the Assistance Publique-Hôpitaux de Paris network (38 hospitals).
• Professor of Cardiology at Université Paris-Cité, Paris, France
• Chair of the FACT (French Alliance for cardiovascular Clinical Trials) academic research network.
• Chair of the French National University Council for Cardiology (Conseil National des Universités)
• Senior Professor (innovation chair) at Institut Universitaire de France, since 2022

Dr Steg has extensive experience as a clinical trialist in coronary artery disease and has authored more than 1 700 peer-reviewed articles. His H-Index is 149 and he has > 130 000 citations. He has been ”highly cited researcher” every year since 2014. He is Senior Associate Editor for Circulation.